ResMed
RMD
Market cap $36.6B

249.34 USD

-2.87

1.14%

At close Jun 13, 4:00 PM EDT

After hours

249.23

-0.11

0.04%

1 day

-1.14%

5 days

-1.06%

1 month

0.68%

3 months

13.48%

6 months

4.54%

Year to date

9.13%

1 year

17.40%

5 years

52.27%

10 years

325.86%

About: ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Employees: 9,980

Healthcare Medical Instruments & Supplies

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

25% more first-time investments, than exits

New positions opened: 105 | Existing positions closed: 84

20% more repeat investments, than reductions

Existing positions increased: 339 | Existing positions reduced: 283

1.65% more ownership

Funds ownership: 61.34% [Q4 2024] → 62.99% (+1.65%) [Q1 2025]

1% more funds holding

Funds holding: 854 [Q4 2024] → 859 (+5) [Q1 2025]

0% more capital invested

Capital invested by funds: $20.6B [Q4 2024] → $20.7B (+$86.8M) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 7 [Q4 2024] → 7 (+0) [Q1 2025]

65% less call options, than puts

Call options by funds: $118M | Put options by funds: $340M

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$248

1%

downside

Avg. target

$270

8%

upside

High target

$290

16%

upside

6 analyst ratings

4 positive

67%

2 neutral

33%

0 negative

0%

RBC Capital Craig Wong-Pan	2%upside $255	Sector Perform Maintained	24 Apr 2025
UBS Laura Sutcliffe	14%upside $285	Buy Maintained	24 Apr 2025
JP Morgan David Low	16%upside $290	Overweight Maintained	24 Apr 2025
Piper Sandler Adam Maeder	1%downside $248	Neutral Maintained	24 Apr 2025
Keybanc Brett Fishbin	10%upside $274	Overweight Maintained	24 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about RMD published over the past 30 days

The Motley Fool

ResMed: A Mixed Bag for Investors Amid Rising Competition

Explore the exciting world of ResMed (RMD 0.64%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

ResMed: A Mixed Bag for Investors Amid Rising Competition

ResMed: A Sleeping Giant Hiding In Plain Sight

ResMed dominates an enormous, underdiagnosed market with recurring revenue and digital health leadership, yet trades below its historical earnings multiples, offering compelling value. The company's sticky, essential products and expanding digital platform create a powerful, recession-resistant business model with strong secular tailwinds. We forecast 10% compound annual growth through 2030, with shares offering 13-21% upside based on reasonable valuation multiples and robust earnings growth.

ResMed: A Sleeping Giant Hiding In Plain Sight

Zacks Investment Research

ResMed (RMD) is a Top-Ranked Growth Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

ResMed (RMD) is a Top-Ranked Growth Stock: Should You Buy?

Top 15 High-Growth Dividend Stocks For June 2025

My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in May, gaining 6.45% versus SPY's 6.28% and VIG's 3.61%. The list's year-to-date return is 6.07%, beating SPY every month in 2025, though still short of my 12% annualized target. The June 2025 Top 15 stocks offer a 1.34% average dividend yield with a 22.82% 5-year dividend growth rate and are 25% undervalued.

Top 15 High-Growth Dividend Stocks For June 2025

Zacks Investment Research

ResMed (RMD) Up 4% Since Last Earnings Report: Can It Continue?

ResMed (RMD) reported earnings 30 days ago. What's next for the stock?

ResMed (RMD) Up 4% Since Last Earnings Report: Can It Continue?

Zacks Investment Research

Is it Worth Retaining ResMed Stock in Your Portfolio Now?

RMD gains on strong mask sales and digital health growth, but faces macro headwinds and fierce competition.

Is it Worth Retaining ResMed Stock in Your Portfolio Now?

Zacks Investment Research

Here's Why ResMed (RMD) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why ResMed (RMD) is a Strong Growth Stock

The Motley Fool

3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term

You may be surprised at how much wealth you can build by buying strong growth stocks and holding them over the long term. Investing in solid, growing businesses is one of the best ways you can earn the money needed to prepare yourself for a comfortable retirement.

3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term

Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025

SAN DIEGO and LONDON and DUBLIN and SYDNEY, May 15, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, has been named the Official Sleep Partner of the Qatar Airways British & Irish Lions Tour to Australia. The Tour brings rugby fans' dreams to life over a six-week period.

Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025

Top 15 High-Growth Dividend Stocks To Consider For May 2025

My Top 15 High-Growth Dividend stocks for April 2025 outperformed SPY and VIG, posting a 0.12% gain versus SPY's -0.87% and VIG's -1.53%. Year-to-date, the Top 15 list returned -0.36%, outperforming VIG's -2.46% and SPY's -5.40%, aiming for a long-term 12% return. The May 2025 Top 15 stocks offer a 1.33% average dividend yield with a 21.25% 5-year dividend growth rate and are 29% undervalued.

Top 15 High-Growth Dividend Stocks To Consider For May 2025

See News Rankings

Charts implemented using Lightweight Charts™